Pharmacokinetic/pharmacodynamic relationship of danofloxacin agaisnt Mannheimia haemolytica in a tissue-cage model in calves

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 2, 2003, Pages 253-257

  Greko, Christina ^a   Finn, Maria ^a   Franklin, Anders ^a   Bengtsson, Björn ^a  

^a NATIONAL VETERINARY INSTITUTE   (Sweden)

Author keywords

Fluoroquinolones; In vivo models; Mannheimia; Pharmacodynamics; Tissue cages

Indexed keywords

DANOFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CATTLE; CLINICAL STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MODEL; DRUG HALF LIFE; DRUG TISSUE LEVEL; EXPERIMENTAL MODEL; GRAM NEGATIVE BACTERIUM; HOST RESISTANCE; IN VITRO STUDY; MALE; MANNHEIMIA HAEMOLYTICA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREDICTION; VALIDATION PROCESS;

ANIMALS; ANTI-INFECTIVE AGENTS; CATTLE; DIFFUSION CHAMBERS, CULTURE; FLUOROQUINOLONES; MALE; MANNHEIMIA HAEMOLYTICA; PASTEURELLACEAE INFECTIONS;

EID: 0041527010     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg339     Document Type: Article

References (29)

1. Andes, D. & Craig, W. A. (2002). Animal model pharmacokinetics and pharmacodynamics: a critical review. International Journal of Antimicrobial Agents 19, 261-8.
2. MacGowan, A. & Bowker, K. (2002). Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models. International Journal of Antimicrobial Agents 19, 291-8.
3. Frimodt-Moller, N. (2002). How predictive is PK/PD for antibacterial agents? International Journal of Antimicrobial Agents 19, 333-9.
4. Clarke, C. R. (1989). Tissue-chamber modeling system-applications in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics 12, 349-68.
5. Bengtsson, B., Bredberg, U. & Luthman, J. (1992). Mathematical description of the concentration of oxytetracycline and penicillin-G in tissue cages in calves as related to the serum concentration. Journal of Veterinary Pharmacology and Therapeutics 15, 202-16.
6. Xuan, D., Zhong, M., Mattoes, H. et al. (2001). Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. Antimicrobial Agents and Chemotherapy 45, 794-9.
7. Aliabadi, F. S. & Lees, P. (2002). Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate. Journal of Veterinary Pharmacology and Therapeutics 25, 161-74.
8. Bengtsson, B. & Greko, C. (2002). Simulation of concentration-profiles of benzyl-penicillin, enrofloxacin and dihydrostreptomycin in tissue cages in calves. Journal of Veterinary Pharmacology and Therapeutics 25, 389-92.
9. Greko, C., Finn, M., Öhagen, P. et al. (2003). A tissue cage model in calves for studies on pharmacokinetic/pharmacodynamic interactions of antimicrobials. International Journal of Antimicrobial Agents, in press.
10. National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Fourth Edition: Approved Standard M7-A4. NCCLS, Wayne, PA, USA.
11. Bengtsson, B., Luthman, J. & Jacobsson, S.-O. (1984). Evaluation of a tissue cage model for use in cattle. Acta Veterinaria Scandinavica 25, 480-94.
12. Chapin-Robertsson, K. & Edberg, S. C. (1991). Measurement of antibiotics in human body fluids: Techniques and significance. In Antibiotics in Laboratory Medicine, 3rd edn (Lorian, V., Ed.), pp. 295-366. Williams & Wilkins, Baltimore, MD, USA.
13. Craig, W. & Suh, B. (1991). Protein binding and the antimicrobial effects: methods for the determination of protein binding. In Antibiotics in Laboratory Medicine, 3rd edn (Lorian, V., Ed.), pp. 367-402. Williams & Wilkins, Baltimore, MD, USA.
14. Vogelman, B., Gudmundsson, S., Legget, J. et al. (1988). Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. Journal of Infectious Diseases 158, 831-47.
15. Mouton, J. W., Dudley, M. N., Cars, O. et al. (2002). Standardization of the pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. International Journal of Antimicrobial Agents 19, 355-8.
16. Friis, C. (1993). Penetration of danofloxacin into the respiratory tract tissues and secretions of calves. American Journal of Veterinary Research 54, 1122-7.
17. Gunderson, B. W., Ross, G. H., Ibrahim, K. H. et al. (2001). What do we really know about antibiotic pharmacodynamics? Pharmacotherapy 21, 302S-18S.
18. Forrest, A., Nix, D. E., Ballow, C. H. et al. (1993). Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents and Chemotherapy 37, 1073-81.
19. Forrest, A., Chodosh, S., Amantea, M. A. et al. (1997). Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 40, Suppl. A, 45-57.
20. Meinl, B., Hyatt, J. M., Forrest, A. et al. (2000). Pharmacokinetic/pharmacodynamic predictors of time to clinical resolution in patients with acute bacterial exacerbations of chronic bronchitis treated with a fluoroquinolone. International Journal of Antimicrobial Agents 16, 273-80.
21. MacGowan, A. P., Rogers, C., Wootton, M. et al. (2000). Assessment of different antibacterial measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations with moxifloxacin. Journal of Antimicrobial Chemotherapy 46, 73-8.
22. MacGowan, A. P., Wootton, M. & Holt, H. A. (1999). The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility. Journal of Antimicrobial Chemotherapy 43, 345-9.
23. Madaras-Kelly, K. J., Ostergaard, B. E., Hovde, L. B. et al. (1996). Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy 40, 627-32.
24. Andes, D. & Craig, W. A. (2002). Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrobial Agents and Chemotherapy 46, 1665-70.
25. Fernandez, J., Barrett, J. F., Licata, L. et al. (1999). Comparison of efficacies of oral levofloxacin and oral ciprofloxacin in a rabbit model of a staphylococcal abscess. Antimicrobial Agents and Chemotherapy 43, 667-71.
26. Lacy, M. K., Lu, W., Xu, X. et al. (1999). Pharmacodynamic comparisons of levofloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrobial Agents and Chemotherapy 43, 672-7.
27. Hershberger, E. & Rybak, M. J. (2000). Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model. Antimicrobial Agents and Chemotherapy 44, 598-601.
28. Lindencrona, R. H., Friis, C. & Aarestrup, F. M. (2000). The pharmacodynamic effect of amoxicillin and danofloxacin against Salmonella typhimurium in an in-vitro pharmacodynamic model. Research in Veterinary Science 68, 261-4.
29. Aliabadi, F. S. & Lees, P. (2001). Pharmacokinetics and pharmacodynamics of danofloxacin in serum and tissue fluids of goats following intravenous and intramuscular administration. American Journal of Veterinary Research 62, 1979-89.